• Publications
  • Influence
Intestinal Inhibition of the Na+/H+ Exchanger 3 Prevents Cardiorenal Damage in Rats and Inhibits Na+ Uptake in Humans
An inhibitor of intestinal NHE3 reduces absorption of dietary sodium in rats and humans and prevents salt-induced cardiorenal injury in nephrectomized rats and suggests that therapeutic alteration of sodium transport in the gastrointestinal tract instead of the kidney could lead to improved sodium management in renal disease. Expand
Effect of RenaGel, a non-absorbable, cross-linked, polymeric phosphate binder, on urinary phosphorus excretion in rats.
RenaGel, a novel, non-absorbed hydrogel which binds dietary phosphate leading to increased fecal excretion, decreased absorption and decreased serum phosphorus levels is developed, indicating that RenaGel is a potent phosphate binder. Expand
Efficacy of Tenapanor in Treating Patients With Irritable Bowel Syndrome With Constipation: A 12-Week, Placebo-Controlled Phase 3 Trial (T3MPO-1)
Tenapanor 50 mg b.i.d. improved IBS-C symptoms and was generally well tolerated, offering a potential new treatment option for patients with IBS -C. Expand
Tenapanor Treatment of Patients With Constipation-Predominant Irritable Bowel Syndrome: A Phase 2, Randomized, Placebo-Controlled Efficacy and Safety Trial
Tenapanor 50 mg b.i.d. significantly increased stool frequency and reduced abdominal symptoms in patients with IBS-C, and further research into tenapanor as a potential treatment for these patients is justified. Expand
Effect of Tenapanor on Serum Phosphate in Patients Receiving Hemodialysis.
Tenapanor treatment resulted in statistically significant, dose-dependent reductions in serum phosphate concentrations in patients with hyperphosphatemia receiving hemodialysis, and diarrhea was the most common adverse event. Expand
Absorption, distribution and excretion of GT31-104, a novel bile acid sequestrant, in rats and dogs after acute and subchronic administration.
Analysis of gastrointestinal (GI) tract tissues with contents indicated that GT31-104 is rapidly cleared from the GI tract, indicating that the novel bile acid sequestrant is not absorbed from theGI tract in rats and dogs. Expand
Effects of Tenapanor on Cytochrome P450‐Mediated Drug‐Drug Interactions
It is suggested that tenapanor can be coadministered with CYP3A4‐metabolized drugs without affecting their exposure and found findings were similar for metabolites of midazolam. Expand
Tenapanor administration and the activity of the H+‐coupled transporter PepT1 in healthy volunteers
It is suggested that tenapanor 15 mg twice daily does not have a clinically relevant impact on the activity of the H+‐coupled transporter PepT1 in humans, and this may guide future research on drug–drug interactions involving NHE3 inhibitors. Expand
Sevelamer, a Phosphate-Binding Polymer, is a Non-Absorbed Compound
ObjectiveTo examine the absorption, distribution and excretion of sevelamer hydrochloride in rats and humans.ParticipantsTwelve male Sprague-Dawley rats were used in the animal study, and twentyExpand
Inhibition of sodium/hydrogen exchanger 3 in the gastrointestinal tract by tenapanor reduces paracellular phosphate permeability
It is determined that tenapanor reduces intestinal phosphate absorption predominantly through reduction of passive paracellular phosphate flux, an effect mediated exclusively via on-target NHE3 inhibition. Expand